# Chapter 4: Chest medicine

## References

1. Johnson DC. Importance of adjusting carbon monoxide diffusing capacity (DLCO) and carbon monoxide transfer coefficient (KCO) for alveolar volume. Respir Med 2000; 94(1):28-37. http://www.resmedjournal.com/article/S0954-6111(99)90740-0/abstract

2. Spira A. Airway gene expression: a novel diagnostic test for lung cancer in smokers. Proc Amer Assoc Cancer Res 2006; 47:242

3. Doerschuk C. Pulmonary alveolar proteinosis - is host defense awry? N Engl J Med 2007; 356: 547-9. http://www.nejm.org/doi/full/10.1056/NEJMp068259

4. NICE. Pneumonia in adults: Diagnosis and management [CG191]. 2014. https://www.nice.org.uk/guidance/cg191

5. Man SY, Lee N, Ip M, et al. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax 2007; 62:348-53. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2092476/

6. Lim WS. Severity assessment in community-acquired pneumonia: moving on. Thorax 2007; 62:287-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2092475/

7. Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis 2007; 44(4):568-76. http://cid.oxfordjournals.org/content/44/4/568.long

8. Stringer JR, Beard CB, Miller RF, et al. A new name for Pneumocystis from humans and new perspectives on the host-pathogen relationship. Emerg Infect Dis 2002; 8(9):891-6.

9. Kaplan JE, Benson C, Holmes KT, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Atlanta, GA: CDC, 2009. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5804a1.htm

10. Hui DS. Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection. Respirology 2008; 13 Suppl 1:S10-3. http://www.ncbi.nlm.nih.gov/pubmed/18366521

11. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian Influenza A (H5N1) Infection in Humans. N Engl J Med 2005; 353:1374-85. http://content.nejm.org/cgi/content/full/353/13/1374

12. Engin A. Influenza type A (H5N1) virus infection. Mikrobiyol Bul 2007; 41(3):485-94. http://www.ncbi.nlm.nih.gov/pubmed/17933264

13. Public Health England. Avian influenza: guidance and algorithms for managing human cases. 2014. https://www.gov.uk/government/publications/avian-influenza-guidance-and-algorithms-for-managing-human-cases

14. Avian influenza guidance and algorithms. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1195733851442

15. British Thoracic Society. Guidelines on severe acute respiratory syndrome. 2004. http://www.brit-thoracic.org.uk/guidelines/severe-acute-respiratory-syndrome-guideline.aspx

16. Hui DS. An overview on severe acute respiratory syndrome (SARS). Monaldi Arch Chest Dis 2005; 63(3):149-57

17. Gumel AB, Nuño M, Chowell G. Mathematical assessment of Canada's pandemic influenza preparedness plan. Can J Infect Dis Med Microbiol 2008; 19(2):185-92. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605860/

18. Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65 Suppl 1:i1-58. http://thorax.bmj.com/content/65/Suppl_1/i1.long

19. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365(18):1663-72. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230303/

20. Rehman A, Baloch NU, Janahi IA. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015; 373(18):1783-4. http://www.nejm.org/doi/pdf/10.1056/NEJMc1510466

21. Alton EW, Armstrong DK, Ashby D, et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015; 3(9):684-91. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673100/

22. NICE. Guidance on the diagnosis and treatment of lung cancer. 2011. http://guidance.nice.org.uk/CG121

23. Bertazzi PA. Descriptive epidemiology of malignant mesothelioma. Med Lav 2005; 96(4):287-303. http://www.ncbi.nlm.nih.gov/pubmed/16457426

24. Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol 2007; 4(6):344-52. http://www.nature.com/nrclinonc/journal/v4/n6/full/ncponc0839.html

25. NICE. Lung cancer: Diagnosis and management [CG121]. 2011. http://guidance.nice.org.uk/CG121

26. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135:805-26. http://www.sciencedirect.com/science/article/pii/S0012369209602099

27. Graf K. Five-years surveillance of invasive aspergillosis in a university hospital. BMC Infect Dis 2011; 11:163. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128051/

28. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15. http://www.nejm.org/doi/full/10.1056/NEJMoa020191

29. Morfín-Maciel B, Barragán-Meijueiro Mde L, Nava-Ocampo AA. Individual and family household smoking habits as risk factors for wheezing among adolescents. Prev Med 2006; 43(2):98-100. http://www.sciencedirect.com/science/article/pii/S0091743506001538

30. Størdal K, Johannesdottir GB, Bentsen BS, et al. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease. Arch Dis Child 2005; 90(9):956-60. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1720585/

31. Douglas JD. If you want to cure their asthma, ask about their job. Prim Care Respir J 2005; 14(2):65-71. http://www.nature.com/articles/pcrj2004122

32. Holloway EA, West RJ. Integrated breathing and relaxation training (the Papworth Method) for adults with asthma in primary care: a randomised controlled trial. Thorax 2007; 62(12):1039-42. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2094294/